Table 3.

Primary outcomes by study arm for each study visit, unadjusted results.

	Control arm	Live call arm	Technology arm
Number of drinking days, prior 21, mean (95 % CI)
Baseline	9.2 (8.6–9.9)	8.8 (8.2–9.5)	10.3 (9.6–11.0)
3–month	5.5 (5.0–6.1)	3.7 (3.3–4.2)	3.2 (2.8–3.6)
6-month	5.5 (5.0–6.1)	2.9 (2.6–3.3)	3.0 (2.6–3.4)
9-month	5.5 (5.0–6.0)	2.2 (1.9–2.5)	2.8 (2.4–3.1)
PEth ng/mL, mean (95 % CI)
Baseline	413.3 (306.6–519.9)	303.9 (230.7–377.1)	506.2 (351.8–660.5)
3-month	380.5 (278.0–483.1)	338.0 (242.8–433.1)	427.0 (314.7–539.4)
6-month	396.9 (290.5–503.4)	376.9 (259.6–494.1)	506.2 (386.1–626.3)
9-month	396.2 (288.1–504.3)	313.8 (220.3–407.4)	500.8 (340.2–661.3)
Viral suppression, % (95 % CI)
Baseline	91.0 % (83.1–96.0)	85.6 % (76.6–92.1)	91.1 % (83.2–96.1)
9-month	92.9 % (85.1–97.3)	95.0 % (87.7–98.6)	94.1 % (86.7–98.0)

Viral load tested at baseline and nine months.